Orthopaedic Surgery - Denosumab

Basics

Denosumab is a fully human IgG2 monoclonal antibody directed against receptor activator of nuclear factor-kappa B ligand (RANKL).

By binding RANKL, denosumab prevents activation of the RANK receptor on osteoclast precursors and mature osteoclasts. This inhibits osteoclast formation, activity, and survival, thereby reducing osteoclast-mediated bone resorption.

Indications

Denosumab is used in disorders associated with excessive osteoclast activity or increased bone turnover.

Important indications include metastatic bone disease, multiple myeloma, postmenopausal osteoporosis, and giant cell tumor of bone.

Giant Cell Tumor of Bone

In giant cell tumor of bone, denosumab may be considered when the lesion is unresectable, metastatic, or when tumor reduction may facilitate a less morbid operation and preservation of bone or an adjacent joint.

Its therapeutic effect is related to inhibition of the RANK/RANKL pathway that is central to formation of the osteoclast-like giant cells within these tumors.

Treatment

Dosing for Giant Cell Tumor and Malignant Bone Disease

For giant cell tumor of bone and selected oncologic indications, denosumab is commonly administered at 120 mg subcutaneously every 4 weeks.

Additional loading doses may be given on days 8 and 15 during the first month of therapy.

Osteoporosis Treatment

Denosumab is also used at a lower cumulative dose for osteoporosis.

The exact regimen depends on the indication and formulation, and treatment should follow the appropriate prescribing protocol for osteoporosis rather than the higher-dose oncologic regimen.

General Measures

Activity

Denosumab itself does not usually require restriction of routine physical activity.

Activity limitations, when present, are generally related to the underlying skeletal disease, fracture risk, or associated treatment rather than to the drug alone.

Dental Procedures

Invasive dental procedures should ideally be addressed before therapy begins whenever feasible.

Elective dental extractions and other procedures involving substantial manipulation of the jaw should be approached cautiously during treatment because of the risk of osteonecrosis of the jaw.

Mechanism of Action

RANKL is required for normal development and activation of osteoclasts.

Denosumab binds RANKL and prevents interaction with the RANK receptor, resulting in a marked decrease in osteoclast-mediated bone turnover.

Unlike bisphosphonates, denosumab does not become permanently incorporated into bone, so its pharmacologic effects diminish after treatment is discontinued.

Complications

Osteonecrosis of the Jaw

One of the most important complications is osteonecrosis of the jaw (ONJ).

The risk generally increases with greater cumulative exposure and is higher in patients receiving high-dose treatment for malignancy.

Risk Factors for Osteonecrosis of the Jaw

Factors associated with greater ONJ risk include longer treatment duration, multiple myeloma, corticosteroid use, diabetes mellitus, antiangiogenic therapy, poor oral hygiene, and invasive dental procedures such as tooth extraction.

Preventive dental care before starting treatment is therefore important.

Dental Evaluation

Patients should undergo an appropriate dental examination before denosumab is initiated, particularly when high-dose oncologic therapy is planned.

Active dental infection or necessary invasive dental treatment should be addressed when possible before exposure.

Atypical Femoral Fracture

Long-term suppression of bone turnover may rarely be associated with atypical femoral fractures.

These fractures may occur in the subtrochanteric region or femoral shaft, extending from just below the lesser trochanter toward the supracondylar region.

Prodromal Femoral Pain

Patients may experience thigh, groin, or hip pain with weight-bearing before an atypical fracture becomes complete.

New unexplained pain in these locations should prompt evaluation for a stress reaction or incomplete fracture.

Reversibility

The antiresorptive effects of denosumab are reversible after treatment is stopped.

Bone turnover can rise substantially after discontinuation, so cessation or interruption of therapy should be planned carefully according to the underlying indication and subsequent osteoporosis or oncologic management.

Hypocalcemia

Denosumab can lower serum calcium because of reduced osteoclastic release of calcium from bone.

Hypocalcemia may be particularly important in patients with renal impairment, vitamin D deficiency, or other disturbances of calcium metabolism.

Patient Monitoring

Dental Examination

A dental assessment should be performed before therapy when clinically appropriate.

During treatment, patients should maintain good oral hygiene and report persistent dental pain, exposed bone, or delayed healing following dental procedures.

Serum Calcium

Serum calcium should be checked before and during treatment.

Calcium and vitamin D supplementation should be provided when indicated to reduce the risk of treatment-associated hypocalcemia.

Symptoms of Hypocalcemia

Patients should be educated about symptoms suggesting low serum calcium.

These may include muscle spasms, twitching, numbness or tingling around the mouth or fingers, facial twitching, and seizures in severe cases.

Monitoring for Stress Fracture

Patients should report new thigh or groin pain during weight-bearing.

When symptoms are suspicious, imaging should be obtained to assess for an incomplete or atypical femoral stress fracture.

Pregnancy

Denosumab should not be used during pregnancy.

Patients with reproductive potential should receive counseling regarding pregnancy avoidance during therapy and for the appropriate period after treatment according to the prescribed regimen.

Patient Teaching

Patients should understand the important warning symptoms associated with therapy, particularly those of hypocalcemia, jaw osteonecrosis, and atypical femoral fracture.

Good dental hygiene, appropriate calcium and vitamin D intake, and prompt reporting of new skeletal pain are important components of treatment.

Frequently Asked Questions

How Long Can Denosumab Be Used?

Treatment duration depends on the underlying indication, fracture or oncologic risk, treatment response, and adverse effects.

Long-term therapy requires periodic reassessment.

Unlike some bisphosphonate regimens, denosumab should not be stopped casually or followed by an unsupervised drug holiday, because rapid rebound in bone turnover can occur after discontinuation.

Can a Patient Become Pregnant While Taking Denosumab?

No. Denosumab is not approved for use during pregnancy.

Patients with reproductive potential should avoid conception during treatment and follow the recommended post-treatment contraception interval.

What Is an Important Contraindication?

Pre-existing hypocalcemia is a major contraindication to starting denosumab.

Serum calcium abnormalities should be corrected before treatment is initiated.